Drug Profile
INCB 8696
Alternative Names: INCB8696Latest Information Update: 14 May 2009
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Anti-inflammatories; Neuropsychotherapeutics
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lupus nephritis; Multiple sclerosis
Most Recent Events
- 31 Dec 2008 INCB 8696 is available for licensing (http://www.incyte.com)
- 31 Dec 2008 Discontinued - Phase-I for Lupus nephritis in USA (PO)
- 31 Dec 2008 Discontinued - Phase-I for Multiple sclerosis in USA (PO)